Fonseca-Silva Daniela, Gomes Rosário, Martins-Oliveira Inês, Silva-Dias Ana, Ramos Maria Helena, Pina-Vaz Cidália
Department of Clinical Pathology, Instituto Português de Oncologia, 4200-072 Porto, Portugal.
FASTinov SA, 4200-135 Porto, Portugal.
Int J Mol Sci. 2025 Jan 21;26(3):883. doi: 10.3390/ijms26030883.
Urinary tract infections caused by Gram-negative bacteria (GNB) are among the most common infections and a significant cause of sepsis. The increasing prevalence of multidrug-resistant (MDR) bacteria poses challenges to empirical treatment. Colistin may be used a last-resort antibiotic for treating MDR infections, but this requires the rapid determination of susceptibility to colistin. Traditional susceptibility testing methods can take up to 48 h, and there are specific challenges in determining colistin susceptibility. This study evaluates a novel, rapid method for determining colistin susceptibility directly from positive urine samples using the FASTcolistin MIC kit from FASTinov. A total of 100 urine samples positive for Gram-negative bacilli when screened by the UF-1000i system were included in this study. After a simple sample prep, the same bacterial suspension was used for identification on MALDI-TOF and inoculated in the FASTcolistin MIC panel for our AST; after incubation at 37 °C for 1 h, it was analyzed via flow cytometry using a CytoFLEX cytometer (Beckman Coulter, Brea, CA, USA). The categorical susceptibility to colistin according to EUCAST or CLSI standards as well as the MIC values were given by bioFAST software (bioFAST 2.0). The essential agreement (EA) and bias were calculated. Different species of Enterobacterales, , and spp. were correctly identified by MALDI-TOF directly from the FASTcolistin MIC sample prep. The essential agreement between the two methods was 99%, with a bias of -17%. Both identification and susceptibility were obtained in less than 2 h. This study presents a rapid and accurate method for determining colistin MIC directly from urine samples. The shortness of time required to produce a result, 2 h versus 48 h with the conventional methods, will significantly impact treatment decisions, especially in urinary tract infections difficult to treat.
革兰氏阴性菌(GNB)引起的尿路感染是最常见的感染之一,也是脓毒症的重要病因。多重耐药(MDR)菌的日益流行给经验性治疗带来了挑战。黏菌素可作为治疗MDR感染的最后手段,但这需要快速确定对黏菌素的敏感性。传统的药敏试验方法可能需要长达48小时,而且在确定黏菌素敏感性方面存在特定挑战。本研究评估了一种使用FASTinov公司的FASTcolistin MIC试剂盒直接从阳性尿液样本中确定黏菌素敏感性的新型快速方法。本研究纳入了100份经UF-1000i系统筛查革兰氏阴性杆菌阳性的尿液样本。经过简单的样本制备后,将相同的细菌悬液用于基质辅助激光解吸电离飞行时间质谱(MALDI-TOF)鉴定,并接种到FASTcolistin MIC板中进行抗菌药物敏感性试验(AST);在37℃孵育1小时后,使用CytoFLEX流式细胞仪(美国加利福尼亚州布雷亚的贝克曼库尔特公司)通过流式细胞术进行分析。根据欧洲抗菌药物敏感性试验委员会(EUCAST)或美国临床和实验室标准协会(CLSI)标准得出的对黏菌素的分类敏感性以及最低抑菌浓度(MIC)值由bioFAST软件(bioFAST 2.0)给出。计算了基本一致性(EA)和偏差。直接从FASTcolistin MIC样本制备物中通过MALDI-TOF正确鉴定出了不同种类的肠杆菌科细菌、 菌属和 菌属。两种方法之间的基本一致性为99%,偏差为-17%。鉴定和药敏结果均在不到2小时内获得。本研究提出了一种直接从尿液样本中确定黏菌素MIC的快速准确方法。与传统方法所需的48小时相比,得出结果所需的2小时时间较短,这将显著影响治疗决策,尤其是在难治性尿路感染中。